Joseph A Markenson
Overview
Explore the profile of Joseph A Markenson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ford A, Siegel M, Bagel J, Cordoro K, Garg A, Gottlieb A, et al.
JAMA Dermatol
. 2018 Jun;
154(8):934-950.
PMID: 29926091
Importance: Psoriasis is a chronic, inflammatory skin disease and has significant associated morbidity and effect on quality of life. It is important to determine whether dietary interventions help reduce disease...
2.
Gharibo C, Argoff C, Markenson J, Webster L, Nezzer J, Solorio D, et al.
Clin J Pain
. 2017 Jun;
34(2):138-144.
PMID: 28591082
Objectives: To report the opioid-sparing effects of SoluMatrix indomethacin, developed using SoluMatrix Fine Particle Technology, in a phase 3 study in patients with acute pain following bunionectomy. Methods: This phase...
3.
Altman R, Strand V, Hochberg M, Gibofsky A, Markenson J, Hopkins W, et al.
Postgrad Med
. 2015 Apr;
127(5):517-28.
PMID: 25913498
Introduction: Diclofenac is used for the treatment of osteoarthritis (OA); however, like other nonsteroidal anti-inflammatory drugs (NSAIDs) it can be associated with serious dose-related adverse events (AEs). Low-dose SoluMatrix® diclofenac...
4.
Markenson J, Koenig A, Feng J, Chaudhari S, Zack D, Collier D, et al.
J Clin Rheumatol
. 2013 Aug;
19(6):317-23.
PMID: 23965479
Background: In rheumatoid arthritis (RA), there is discordance between patient and physician assessments of disease severity and treatment response. Objective: This retrospective analysis of the RADIUS (RA Disease-Modifying Anti-Rheumatic Drug...
5.
Chakravarty S, Markenson J
Curr Opin Rheumatol
. 2012 Nov;
25(1):37-43.
PMID: 23159916
Purpose Of Review: Musculoskeletal complaints are a feature of several endocrine diseases. This review will update clinicians on their association, presentation, and treatment. Recent Findings: To update clinicians on the...
6.
Markenson J, Gibofsky A, Palmer W, Keystone E, Schiff M, Feng J, et al.
J Rheumatol
. 2011 May;
38(7):1273-81.
PMID: 21572150
Objective: To evaluate persistence with anti-tumor necrosis factor (TNF) therapy and predictors of discontinuation in patients with rheumatoid arthritis (RA). Methods: This retrospective analysis used data from RADIUS 1, a...
7.
8.
9.
Gibofsky A, Palmer W, Keystone E, Schiff M, Feng J, McCroskery P, et al.
J Rheumatol
. 2010 Oct;
38(1):21-8.
PMID: 20952478
Objective: to report the rates of serious adverse events (SAE), serious infectious events (SIE), and events of medical interest (EMI) in patients receiving etanercept; to identify the risk factors for...
10.
Markenson J
Curr Opin Rheumatol
. 2009 Nov;
22(1):64-71.
PMID: 19935068
Purpose Of Review: Musculoskeletal complaints accompanying or as a result of endocrine disorders are common and have been well described. This review re-examines these associations in light of newer information...